kausable raises €12M to build AI models that learn and adapt without retraining. German startup kausable, which develops reasoning-first AI models designed to adapt to changing environments without continuous retraining, has secured €12 million in a seed funding round led by UVC Partners and Entourage, with participation from HTGF, Mätch VC, and several AI industry and academic angel investors. * Established in 2025 by Johannes Haux, Dr Benjamin Herdeanu, and Gregor Ramien, kausable is a Heidelberg-based AI startup developing frontier AI models that can learn from limited examples and adapt to new situations without requiring constant retraining. * The company builds causal "world models" that learn cause-and-effect relationships rather than relying solely on patterns identified from large datasets. Its models are trained using synthetic causal data, enabling them to understand how systems behave and apply that knowledge to unfamiliar scenarios with only a small number of examples. * The technology is designed to improve AI efficiency in areas such as robotics, healthcare, forecasting, and industrial systems, where adapting to changing environments remains a major challenge. Details of the deal. * With the fresh capital, the company plans to expand its nine-person team, advance its rapid-learning frontier AI model, and move from research toward commercial applications by testing its technology with early customers across sectors including robotics, healthcare, forecasting, and industrial systems.

Sightera Biosciences closes €3M pre-seed to expand its patient-derived AI drug discovery platform. The funding will expand Sightera's AI-driven drug discovery platform, advance its lead oncology programme towards candidate selection, and strengthen partnerships with pharmaceutical companies. Sightera Biosciences, a Belgian techbio company using generative AI to develop novel small-molecule therapies, has raised €3 million in a pre-seed funding round led by Entourage, Anacura and QBIC. A spin-off from the University of Antwerp and Antwerp University Hospital (UZA), Sightera is developing an AI-native drug discovery platform focused on oncology and fibrosis. Unlike many AI drug discovery companies that rely on public or generic datasets, Sightera trains its models using proprietary data generated from patient-derived biological samples collected from individuals with advanced, therapy-resistant disease. These samples are used to create preclinical models, including organoids, that closely replicate human disease biology and generate large-scale drug-response datasets. The proprietary datasets underpin Sightera's AI platform, enabling it to design small molecules based on biological responses observed in patient-derived systems rather than chemical properties alone. By placing human disease biology at the centre of the discovery process, the company aims to improve the likelihood that AI-designed drug candidates will translate successfully into clinical development. The funding will support the expansion of Sightera's AI-powered drug discovery platform, accelerate the development of its preclinical pipeline and advance its lead molecular glue oncology programme towards preclinical candidate selection. The company also plans to strengthen strategic partnerships with pharmaceutical and biotechnology companies while expanding its research, AI and data science teams. Follow the developments in the technology world. What would you like us to deliver to you?